<DOC>
	<DOC>NCT01913964</DOC>
	<brief_summary>To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.</brief_summary>
	<brief_title>Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>workers who were 18 years of age or older Workers who were infected by HCV and had a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS AmpliPrep/COBAS TaqMan ROCHE) Cirrhotic workers with a ChildPugh score less than 7 workers who had other liver diseases cancer severe jaundice pulmonary and renal chronic diseases, prostatic diseases autoimmune diseases diabetes mellitus decompensated cirrhosis pregnancy cardiopathy hemoglobinopathies hemocromatosis major depression severe psychiatric pathological conditions</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>